
## Guillermo Villacampa Javierre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9512044/publications.pdf Version: 2024-02-01



Guillermo Villacampa

#	Article	IF	CITATIONS
1	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances, 2022, 6, 774-784.	5.2	42
2	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2022, 104, 102352.	7.7	17
3	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2022, 6, 3606-3610.	5.2	35
4	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.9	40
5	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	3.0	10
6	Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. European Radiology, 2021, 31, 1460-1470.	4.5	87
7	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	7.3	54
8	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. Frontiers in Oncology, 2021, 11, 638482.	2.8	16
9	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Leukemia and Lymphoma, 2021, 62, 2288-2291.	1.3	1
10	Patients' and professionals' perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic. Genetics in Medicine, 2021, 23, 1450-1457.	2.4	1
11	Realâ€world evidence of tisagenlecleucel for the treatment of relapsed or refractory large Bâ€cell lymphoma. Cancer Medicine, 2021, 10, 3214-3223.	2.8	73
12	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer, 2021, 148, 134-145.	2.8	10
13	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	5.2	2
14	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology, 2021, 100, 2303-2310.	1.8	32
15	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. European Journal of Cancer, 2021, 155, 168-178.	2.8	1
16	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma, 2020, 61, 1823-1832.	1.3	1
17	Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Experimental Hematology and Oncology, 2020, 9, 37.	5.0	9
18	Clinical outcome and prognostic factors of patients with Richter syndrome: realâ€world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). British Journal of Haematology, 2020, 190, 854-863.	2.5	36

## Guillermo Villacampa

#	Article	IF	CITATIONS
19	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	2.8	16
20	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	7.0	21
21	Clinical and molecular determinants of treatment benefit with phase I trials in patients (pts) with advanced pancreatic cancer (PC) Journal of Clinical Oncology, 2017, 35, 409-409.	1.6	1